AU2019205279A1 - Compositions and methods of treating cancer with glycomimetic peptides - Google Patents
Compositions and methods of treating cancer with glycomimetic peptides Download PDFInfo
- Publication number
- AU2019205279A1 AU2019205279A1 AU2019205279A AU2019205279A AU2019205279A1 AU 2019205279 A1 AU2019205279 A1 AU 2019205279A1 AU 2019205279 A AU2019205279 A AU 2019205279A AU 2019205279 A AU2019205279 A AU 2019205279A AU 2019205279 A1 AU2019205279 A1 AU 2019205279A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- peptide
- group
- pharmaceutical composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614956P | 2018-01-08 | 2018-01-08 | |
| US62/614,956 | 2018-01-08 | ||
| US201862699345P | 2018-07-17 | 2018-07-17 | |
| US62/699,345 | 2018-07-17 | ||
| PCT/US2019/012228 WO2019136185A1 (en) | 2018-01-08 | 2019-01-03 | Compositions and methods of treating cancer with glycomimetic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019205279A1 true AU2019205279A1 (en) | 2020-07-30 |
Family
ID=67143977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019205279A Abandoned AU2019205279A1 (en) | 2018-01-08 | 2019-01-03 | Compositions and methods of treating cancer with glycomimetic peptides |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11376307B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3737365A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7390294B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019205279A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3086751A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019136185A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| WO2023183059A1 (en) * | 2022-03-24 | 2023-09-28 | Susavion Biosciences, Inc. | Method of treatment of neutrophil-driven inflammatory pathologies |
| CA3185526A1 (en) * | 2020-07-28 | 2022-02-03 | Laura L. Eggink | Method of treatment of neutrophil-driven inflammatory pathologies |
| US20230364255A1 (en) * | 2020-08-18 | 2023-11-16 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020715A2 (en) | 2000-09-05 | 2002-03-14 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| US20090246205A1 (en) * | 2004-05-13 | 2009-10-01 | Imclone Systems, Inc | Inhibition of macrophage-stimulating protein receptor (ron) |
| KR101652125B1 (ko) * | 2007-09-26 | 2016-08-29 | 우드라이 파마 게엠베하 | 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질 |
| US8846623B2 (en) * | 2010-10-25 | 2014-09-30 | Academia Sinica | Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis |
| WO2013096829A2 (en) * | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| US20150079071A1 (en) * | 2012-11-30 | 2015-03-19 | The Regents Of The University Of California | Non-catalytic domain targets in matrix metalloprotease proteins for cancer therapies |
| GB201300706D0 (en) * | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
| US10617755B2 (en) * | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| WO2015048477A1 (en) * | 2013-09-27 | 2015-04-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| HUE061339T2 (hu) * | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| US9981044B2 (en) * | 2014-08-30 | 2018-05-29 | Susavion Biosciences, Inc. | Activation of adaptive immune processes for the treatment of cancers and infectious diseases |
| WO2016044716A1 (en) * | 2014-09-19 | 2016-03-24 | The American University In Cairo | Nanoparticle-based combinatorial therapy |
| CA2971471C (en) * | 2014-12-19 | 2023-04-18 | Susavion Biosciences, Inc. | Immunotherapy treatments and compositions |
| EP3288576A4 (en) * | 2015-04-27 | 2019-01-16 | Susavion Biosciences, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS |
| EP3294887A1 (en) * | 2015-05-14 | 2018-03-21 | CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Mirna compositions for the treatment of mature b-cell neoplasms |
| US10688153B2 (en) * | 2015-11-06 | 2020-06-23 | The Board Of Trustees Of The University Of Illinois | Peptides and method for treatment of cardiac arrest |
| UA125026C2 (uk) * | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| CA3026490A1 (en) * | 2016-06-09 | 2017-12-14 | University Of Leicester | Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer |
| AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
-
2019
- 2019-01-03 AU AU2019205279A patent/AU2019205279A1/en not_active Abandoned
- 2019-01-03 US US16/960,267 patent/US11376307B2/en active Active
- 2019-01-03 CA CA3086751A patent/CA3086751A1/en active Pending
- 2019-01-03 EP EP19735760.1A patent/EP3737365A4/en not_active Withdrawn
- 2019-01-03 WO PCT/US2019/012228 patent/WO2019136185A1/en not_active Ceased
- 2019-01-03 JP JP2020537571A patent/JP7390294B2/ja active Active
-
2022
- 2022-06-27 US US17/850,976 patent/US20220331394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019136185A1 (en) | 2019-07-11 |
| EP3737365A1 (en) | 2020-11-18 |
| JP7390294B2 (ja) | 2023-12-01 |
| US11376307B2 (en) | 2022-07-05 |
| EP3737365A4 (en) | 2021-11-03 |
| US20210069285A1 (en) | 2021-03-11 |
| US20220331394A1 (en) | 2022-10-20 |
| CA3086751A1 (en) | 2019-07-11 |
| JP2021509679A (ja) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331394A1 (en) | Compositions and methods of treating cancer with glycomimetic peptides | |
| Schcolnik-Cabrera et al. | Calreticulin in phagocytosis and cancer: opposite roles in immune response outcomes | |
| Zhou et al. | Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases | |
| Liu et al. | Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy | |
| Eggink et al. | An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides | |
| Zhang et al. | Induced sensitization of tumor stroma leads to eradication of established cancer by T cells | |
| Zhang et al. | Macrophage activation by endogenous danger signals | |
| AU2017234192B2 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine | |
| JP2021521776A (ja) | Mage−b2特異性を有するt細胞受容体およびその使用 | |
| EP3813881A2 (en) | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof | |
| KR20220061158A (ko) | 자가면역질환을 치료하기 위한 il-2 접합체 및 사용 방법 | |
| WO2020227159A2 (en) | Methods of modulating immune activity | |
| AU2017382294A1 (en) | Compositions and methods of enhancing or augmenting type I IFN production | |
| Vendetti et al. | The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy | |
| KR102679516B1 (ko) | 면역원성/치료적 당접합체 조성물 및 그의 용도 | |
| Nabergoj et al. | Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy | |
| Yoo et al. | Hyaluronic acid conjugates of TLR7/8 agonists for targeted delivery to secondary lymphoid tissue | |
| AU2016267671B2 (en) | Carbohydrate-modified particles and particulate formulations for modulating an immune response | |
| US11759508B2 (en) | Antigenic peptides for treatment of B-cell malignancy | |
| Shang et al. | Bioengineered nanospores selectively blocking LC3-associated phagocytosis in tumor-associated macrophages potentiate antitumor immunity | |
| Liu et al. | Hyaluronidase-functionalized silica nanocarrier for enhanced chemo-immunotherapy through inducing immunogenic cell death | |
| Eggleton et al. | The therapeutic mavericks: Potent immunomodulating chaperones capable of treating human diseases | |
| WO2015157299A2 (en) | Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells | |
| US20190282683A1 (en) | Immunogenic compositions comprising sbi protein and uses thereof | |
| Lou et al. | TIR domain proteins: regulatory mechanisms in the tumor immune microenvironment, clinical translation strategies, and prospects for precision therapy applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |